(3.235.45.196)
Users online: 1541    [ij] [ij] [ij] 
Email id
 

Research Journal of Pharmacy and Technology
Year : 2016, Volume : 9, Issue : 11
First page : ( 1933) Last page : ( 1936)
Print ISSN : 0974-3618. Online ISSN : 0974-360X.
Article DOI : 10.5958/0974-360X.2016.00396.6

A study on efficacy and safety of etanercept in patients with rheumatoid arthritis

Chaitanya A.*, Kumar M. Ashok, Krishna A. Gokul, Shanmugasundaram P.

Department of Pharmacy Practice, School of Pharmaceutical Sciences, VISTAS, Vels University, Chennai-600117, Tamil Nadu, India

*Corresponding Author E-mail: chaitanya.attirala01@gmail.com

Online published on 2 March, 2017.

Abstract

Aim and objective

To assess the efficacy of Etanercept and also to evaluate the safety profile of Etanercept in patients with Rheumatoid arthritis. The main objectives of the study are to evaluate the drug safety and efficacy among the Rheumatoid arthritis patients. And to monitor the ADRs observed in Rheumatoid arthritis patients with Etanercept.

Materials and Methods

Study was carried out in a 300 bedded tertiary care hospital. The department selected for the study was orthopaedics. This method involves prospective observational analysis of Efficacy and safety of Etanercept in patients with Rheumatoid arthritis. The study was carried out by the collection and documentation of general information of the patient including personal history, past medical history, past medication history, lab investigations and treatment pain will be analysed by using visual analog scale(vas). ADR's were assessed by using Naranjo adverse drug reaction probability scale. The whole procedure was carried out in Rheumatoid arthritis patients who received Etanercept without any alteration in therapy.

Result and Discussion

This study on sample size of 35 was carried out to assess the short term safety and efficacy of Etanercept. Moreland et al compared placebo, ETN 10 mg twice weekly (ETN20), and ETN 25 mg twice weekly (ETN50) in patients with long-standing RA and an inadequate response to DMARDs. Although both treatment arms were significantly better than placebo, as measured by American College of Rheumatology. The study conducted by Elizabeth Mary Curtis et al., shows that Etanercept is a safe and well-tolerated treatment for RA, And another study conducted by Boulos Haraoui et al, study shows that Etanercept is both safe and effective to use in RA. Etanercept has been shown not only to reduce disease activity but also to limit progression of joint damage in early and late disease which are similar to our study.

Conclusion

This study concludes incidence of rate of patients in the age group of 50–59 years were mostly affected by Rheumatiod arthritis compared to other age groups. The male patients were found to be affected more with rheumatoid arthritis than female patients. The study made use of 25mg Eternacept for the above obtained results. This could also be carried out using 50mg Eternacept and evaluated on the same. There was a decrease in pain VAS scale confirming the efficacy and safety of Etanercept. In the future, this study could be further extended to a combination therapy over longer duration of time for better results.

Top

Keywords

Eternacept, Rheumatoid arthritis, VAS Score, Naranjo Scale, Efficacy and safety, Prospective observational study.

Top

  
║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
435,076,701 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.